We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0Q1G market cap is 77.68B. The company's latest EPS is USD 5.5202 and P/E is 143.12.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.32B | 24.56B | 28.32B | 28.54B | 34.12B |
| Operating Income | 5.47B | 6.06B | 6.66B | 7.37B | 6.46B |
| Net Income | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 39.29B | 46.63B | 48.81B | 49.49B | 64.01B |
| Total Liabilities | 36.59B | 40.81B | 39.65B | 38.71B | 53.14B |
| Total Equity | 2.7B | 5.83B | 9.15B | 10.78B | 10.86B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.84B | 6.5B | 7.26B | 7.08B | 4.24B |
| Investing | -8.08B | -2.26B | -2.76B | -3.26B | -7.15B |
| Financing | -2.32B | -3.14B | -4.13B | -5.41B | 3.5B |
| Market Cap | 77.68B |
| Price to Earnings Ratio | 143.12 |
| Price to Sales Ratio | 21.98 |
| Price to Cash Ratio | 266.08 |
| Price to Book Ratio | 69.04 |
| Dividend Yield | - |
| Shares Outstanding | 949.31M |
| Average Volume (1 week) | 240 |
| Average Volume (1 Month) | 327 |
| 52 Week Change | 0.00% |
| 52 Week High | 81.83 |
| 52 Week Low | 81.83 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Eli Lilly And Co |
| Address |
334 north senate avenue indianapolis, indiana 46204 |
| Website | https://www.lilly.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
